Microglial neurotoxicity

Microglial neurotoxicity is a pathological process rather than a single molecular target, characterized by the chronic or excessive activation of microglia that leads to neuronal damage and death (Block et al., Nature Reviews Neuroscience, 2007). In response to various stimuli such as protein aggregates or systemic inflammation, microglia transition into a pro-inflammatory state where they release neurotoxic mediators, including reactive oxygen species (ROS), nitric oxide, and cytokines like TNF-alpha and IL-1beta (Glass et al., Cell, 2010). This mechanism is a central driver in the progression of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS) (Colonna & Butovsky, Annual Review of Immunology, 2017). Therapeutic interventions do not target 'microglial neurotoxicity' as a protein but instead focus on specific receptors and enzymes within the microglial signaling cascade—such as TLR4, NLRP3, or TREM2—to dampen the inflammatory response and preserve neuronal integrity. Effectively modulating this process requires a delicate balance to suppress harmful neuroinflammation without compromising the essential debris-clearing and homeostatic roles that microglia perform in the healthy brain (Hickman et al., Nature Neuroscience, 2018).

Other names

Microglia-mediated neurotoxicityMicroglial-induced neurodegenerationNeurotoxic microglial activationPro-inflammatory microglial polarizationMicrogliosis-mediated neuronal death

Drugs targeting this process typically act by inhibiting pro-inflammatory signaling pathways (e.g., NF-kappaB, p38 MAPK), blocking the NLRP3 inflammasome, antagonizing Toll-like receptors (TLRs), or promoting a phenotypic shift from a neurotoxic (M1-like) to a neuroprotective (M2-like) state to reduce the secretion of reactive oxygen species and inflammatory cytokines.